Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2007

View Archived Issues

SuperGen presents overview of preclinical pipeline

Targeting topoisomerase II with R-16 induces apoptosis and cell cycle arrest in tumor cell lines

Recent patents disclose novel anticancer compounds

Resveratrol analogue M-8 active against melanoma cells

BAY-65-5811 and doxorubicin synergistic against melanoma cells

Hepatitis E virus vaccine effective in phase II study

Novel agents for inflammatory disorders disclosed in recent patents

Recent Merck Frosst patent describes new treatment option for atherosclerosis

HanAll licenses Nautilus compounds for South Korea

MK-2048 shows in vitro activity against resistant HIV-1 mutants

ProNAi and Novosom collaborate on DNAi-based cancer therapeutics

Novartis extends research collaboration with Idera

New formulation of oral methylnaltrexone begins clinical testing

Avalon and Merck & Co. collaborate in cancer

Phosphagenics extends transdermal technology platform

Affectis and Mitsubishi extend research collaboration

ZymoGenetics updates plans for rhThrombin

Crucell to receive funding in development of AdVac-based TB vaccine

Acrux and Organon sign new agreement in women's health

Novel polyamine biosynthesis inhibitor shows potential to prevent HIV/SIV-related encephalitis

ABT-894 begins phase II study for ADHD

Genta and IDIS sign compassionate use agreement for Ganite and Genasense

Stemline Therapeutics in-licenses worldwide rights to SL-401

RVX-208 completes toxicology studies on way to IND filing

NeuroVax studied in new phase II trial for relapsing-remitting MS

New phase I/II trial studies Ferritarg P for Hodgkin's disease

Financing at Potentia to support AMD program

AS-1404 with carboplatin and paclitaxel shows good response rate in NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...